Disulfiram bolsters T‐cell anti‐tumor immunity through direct activation of LCK‐mediated TCR signaling

Qinlan Wang,Ting Zhu,Naijun Miao,Yingying Qu,Zhuning Wang,Yinong Chao,Jing Wang,Wei Wu,Xinyi Xu,Chenqi Xu,Li Xia,Feng Wang

DOI: https://doi.org/10.15252/embj.2022110636

2022-06-01

The EMBO Journal

Abstract:The FDA‐approved drug disulfiram, previously used to treat alcohol dependency, directly activates T‐cell receptor signaling to activate CD8+ T cells and exerts potent anti‐tumor effects in vivo and in vitro. Activation of the T‐cell antigen receptor (TCR)–CD3 complex is critical to induce the anti‐tumor response of CD8+ T cells. Here, we found that disulfiram (DSF), an FDA‐approved drug previously used to treat alcohol dependency, directly activates TCR signaling. Mechanistically, DSF covalently binds to Cys20/Cys23 residues of lymphocyte‐specific protein tyrosine kinase (LCK) and enhances its tyrosine 394 phosphorylation, thereby promoting LCK kinase activity and boosting effector T cell function, interleukin‐2 production, metabolic reprogramming, and proliferation. Furthermore, our in vivo data revealed that DSF promotes anti‐tumor immunity against both melanoma and colon cancer in mice by activating CD8+ T cells, and this effect was enhanced by anti‐PD‐1 co‐treatment. We conclude that DSF directly activates LCK‐mediated TCR signaling to induce strong anti‐tumor immunity, providing novel molecular insights into the therapeutic effect of DSF on cancer.